Effect of XELOX on functional ability among elderly patients with metastatic colorectal cancer: Results from the FNCLCC/GERICO 02 phase II study

Rousseau, Frédérique; Bugat, R.; Ducreux, Michel; Cvitkovic, F.; Carola, Élisabeth; Gisselbrecht, Mathilde; Viret, F.; Esterni, Benjamin; Genève, Jean; Brain, Étienne

doi:10.1016/j.jgo.2010.11.002

Cited by 3 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Il permit de conclure à la faisabilité d'un tel schéma « tout oral » après 70 ans [28]. La seconde phase II avec plan en trois étapes de Fleming se focalisa sur les cancers colorectaux avancés, avec un traitement mixte associant capécitabine orale et oxaliplatine intraveineuse [27]. Comme pour l'essai précédent, une augmentation des doses prudentes initiales était autorisée après le cycle 3 en cas de tolérance satisfaisante.…”

unclassified

GERICO: dix ans de recherche clinique en oncogériatrie

2011

View full text Add to dashboard Cite

Clinical research in geriatric oncology is under active development, since aging is heterogeneous and requires specific programs addressing both old and new therapeutic strategies in elderly cancer patients. The group of geriatric oncology, GERICO, launched in 2002 by the French National Federation of Cancer Centres (FNCLCC), has acquired and demonstrated this specific experience. Convinced of the need to integrate the dimensions of functional status and quality of lifekey issues in the elderly-it has built several trials on primary endpoints derived from geriatric assessment, different from the traditional tumour response and survival. Today it plans to integrate again classical criteria with geriatric ones. It militates in favour of inclusion of a lower selection of populations and takes into consideration life expectancy which remains so difficult to estimate. To cite this journal: Oncologie 13 (2011).

show abstract

unclassified